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OBJECTIVES: To examine inpatient dosing patterns and ery-
thropoietic treatment costs in cancer and pre-dialysis chronic
kidney disease (pCKD) elderly inpatients treated with erythro-
poietic agents from a hospital pharmacy perspective.
METHODS: Analysis of electronic inpatient records from the
Premier Perspective Database©, Premier Inc. Charlotte, NC, was
conducted. Subjects were identiﬁed through hospitalizations
recorded between 7/2002–3/2005 from >500 hospitals nation-
wide. Elderly patients (≥65 years) with an admitting diagnosis of
cancer or pCKD and receipt of EPO or DARB during hospital-
ization were included. Patients receiving dialysis or both agents
were excluded. For cancer and pCKD indications, baseline
demographics, severity of illness, inpatient length of stay, cumu-
lative administered dose, and drug costs were compared between
EPO and DARB patients. May 2006 wholesale acquisition costs
were used to calculate erythropoietic costs. RESULTS: A total of
13,940 hospitalizations (EPO:12,512; DARB:1428) for inpa-
tients with cancer and 42,856 (EPO:38,538; DARB:4318) for
inpatients with pCKD were identiﬁed. For both indications,
patient characteristics were comparable between the two groups.
Mean cumulative administered dose per inpatient stay (cancer:
EPO 59,529 +/− 48,182 Units, DARB 292 +/− 613 mcg; pCKD:
EPO 39,497 +/− 39,851 Units, DARB 184 +/− 348 mcg) resulted
in a dose ratio between EPO and DARB of 204 : 1 and 215 : 1
(Units EPO: mcg DARB) for cancer and pCKD inpatients,
respectively. Based on cumulative administered dose/hospitaliza-
tion, the price premium associated with DARB drug cost was
>70% when compared to EPO for both oncology and pCKD
inpatients (oncology: EPO $724 vs. DARB $1299 p < 0.0001;
pCKD: EPO $481 vs. DARB $818, p < 0.0001). CONCLU-
SION: Based on the evidence from this large retrospective analy-
sis of elderly inpatients, EPO was signiﬁcantly less costly
compared with DARB in both therapeutic areas. These results
are similar to those observed in elderly patients in the outpatient
setting with pCKD or cancer; and mirror results observed in
inpatients <65 years.
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OBJECTIVES: The study objective is to characterize ﬁrst-,
second- and third-line chemotherapy use and costs for patients
with NSCLC from a payer’s perspective. METHODS: Enroll-
ment and claims records from a large, multistate private health
insurance plan were utilized to identify study subjects. Criteria
for analysis include subjects aged 21 years and older, with ≥3
ICD-9 diagnosis codes for NSCLC from January 2002 to Decem-
ber 2005 and continuous enrollment for 12 months prior to diag-
nosis. An algorithm was developed to identify ﬁrst-, second-, and
third-line agents based on chemotherapy (J-codes) sequencing
and delivery dates (CPT codes). Charge data were applied to esti-
mate costs. Direct medical care costs (inpatient, outpatient, phar-
macy, skilled nursing facility) were estimated over 12 and 24
months using the Kaplan-Meier Sample Average estimator to
account for deaths and disenrollments. RESULTS: A total of
42% of NSCLC cases received chemotherapy (n = 3323);
1860/3323 met criteria for analysis. Average age was 63 years
(range 26–103) and 44% were female. Most common therapies
(number of patients): ﬁrst-line: carboplatin + paclitaxel (939),
carboplatin + etoposide (321), carboplatin + gemcitabine (196),
carboplatin + docetaxel (185); second-line: docetaxel (98), geﬁ-
tinib (77), erlotinib (49), gemcitabine (37); third-line: geﬁtnib
(35), pemetrexed (14), erlotinib (13), carboplatin + paclitaxel
(13). Number starting treatment (%), mean observed treatment
time in months: ﬁrst-line only: 1332 (72%), 8; ﬁrst-/second-line:
375 (20%), 11; ﬁrst-/second-/third-line: 153 (8%), 14. Mean
costs (12 months): ﬁrst-line only: $136,385 (SE-2254); ﬁrst-/
second-line: $176,052 (SE-5040); ﬁrst-/second-/third-line:
$215,077 (SE-8215). Mean costs (24 months): ﬁrst-line only:
$153,752 (SE-3367); ﬁrst-/second-line: $213,528 (SE-7265);
ﬁrst-/second-/third-line: $277,007 (SE-12288). CONCLUSION:
Less than 1/3 of NSCLC patients receive second- and third-line
chemotherapy. Although treatment duration was longer for
patients receiving multiple lines of therapy, additional lines of
treatment did not signiﬁcantly increase average monthly costs
($19,500).
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OBJECTIVES: Trastuzumab, a monoclonal antibody, is admin-
istered intravenously as monotherapy or in combination with
chemotherapy in patients with metastatic breast cancer (MBC)
whose tumors over express HER2. This study assessed the cost
components of providing trastuzumab-based combination IV
therapies to women with MBC. METHODS: An administrative
claims database of >60 multi-specialty medical practices/clinics
in the US was used to identify women with MBC (ICD-9 code
174 including 196–198) between January 01, 2003 and May 31,
2006 and receiving trastuzumab plus another IV therapy. Allow-
able amounts for a claim, which closely represents the actual
payments to providers, were used to estimate costs cost per IV
administration visit. Billable cost components were categorized
based on published literature. RESULTS: A total of 151 patients
with 1292 clinic visits receiving any of 7 trastuzumab-based
combination IV therapies were identiﬁed. The total mean cost
per visit across all trastuzumab-based combinations was $3511
of which 70% was accounted for by drugs, 11% by adminis-
tration of the IV and 19% for other visit-related services, which
include supplies and equipment, evaluation and management ser-
vices, and other concomitantly administered IV or oral drugs.
Trastuzumab plus paclitaxel was the most commonly used com-
bination with non-drug costs accounting for 32% ($1072) of
total costs ($3341) per visit. The non-drug costs associated with
administration of the second most commonly used combination,
trastuzumab plus vinorelbine, were 24% ($612) of total costs
($2563) per visit. CONCLUSION: Excluding drug costs, costs
associated with IV administration of trastuzumab-based combi-
nation therapies and other visit-related services are approxi-
